Uses of tricyclic compounds

Details Uses of tricyclic compounds Uses of tricyclic compounds

2007-07-24

2007-07-24

Berch, Mark L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S267000

Reexamination Certificate

active

10349935

ABSTRACT:
Novel tricyclic compounds are disclosed having the general structure of Formulas I or II:were R1, R2 and R3 are defined in the written description of the invention. The compounds are useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by intracellular cytokine signaling.

REFERENCES:
patent: 3770741 (1973-11-01), Goldman
patent: 4228164 (1980-10-01), Szebeni et al.
patent: 4515795 (1985-05-01), Hinze et al.
patent: 4558051 (1985-12-01), Sunshine et al.
patent: 5039666 (1991-08-01), Novick
patent: 5629423 (1997-05-01), Klein et al.
patent: 5648357 (1997-07-01), Bianco et al.
patent: 5734051 (1998-03-01), Spicer et al.
patent: 5780476 (1998-07-01), Underiner et al.
patent: 5801182 (1998-09-01), Klein et al.
patent: 6075029 (2000-06-01), Klein et al.
patent: 2157726 (1973-07-01), None
patent: 1536492 (1978-12-01), None
patent: 2006765 (1981-03-01), None
patent: 213881 (1968-03-01), None
patent: WO94/22449 (1994-10-01), None
patent: WO94/22863 (1994-10-01), None
patent: WO94/24133 (1994-10-01), None
patent: WO95/20589 (1995-08-01), None
patent: WO95/22546 (1995-08-01), None
patent: WO 95 35300 (1995-12-01), None
patent: WO 99 36073 (1999-07-01), None
patent: WO 00 61583 (2000-10-01), None
patent: WO 00/61583 (2000-10-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Anonymous, Expert Opinion on Therapeutic Patents, 2002, vol. 12, No. 7, pp. 1103-1105.
Francis J Dumont, Expert Opinion on Therapeutic Patents (Ashley Publications), 2002, vol. 12, No. 3, pp. 341-367.
Robert H Wiltrout; Jon M Wigginton, Expert Opinion on Biological Therapy (Ashley Publications), 2002, vol. 2, No. 5, pp. 513-524.
David J.W. Grant, “University of Minnesota—Twin Cities Campus College of Pharmacy, Annual Report”, [online] 1999, [retrieved on Feb. 13, 2003]. Retrieved from the internet, <http://www.msi.umn.edu/general/Reports/ar99/departments/pharmacy.html>.
Vippagunta, S. R. et al, Advanced Drug Delivery Reviews, 48, 3-26, 2001.
Cytokines <http://www.whfreeman.com/immunology/CH13/cytokines.htm> dowloaded from the internet May 10, 2006.
IL-1 pathway <http://bio.ifom-firc.it/biobase/transpath/4.1/doc/doc/maps/IL-1.html> downloaded from the internet May 10, 2006.
Interleukin 4 (IL-4) Pathway <http://www.activemotif.com/resources/pathways/il4> Dowloaded from the internet May 10, 2006.
Yang et al., Acta Pharmacol Sin. Dec. 2004;25(12):1666-70.
Barnes et al., Eur Respir J. Mar. 1994;7(3):579-91.
Trinchieri, Giorgio, Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells with Immunoregulatory Functions in the Generation of T-Helper Cell Type 1 and Cytotoxic Lymphocytes,Blood, 84: 4008-4027 (1994).
Kennedy, Mary, et al., “Interleukin-12 Regulates the Proliferation of Th1, but not Th2 or Th0, Clones”,Eur. J. Immunol., 24:2271-2278, 1994.
Morris, S.C. et al., “Effects of IL-12 on in Vivo Cytokine Gene Expression and Ig Isotype Selection”,J. Immunol, 152:1047 (1994).
McKnight, A.J., et al., “Effects of IL-12 on Helper T Cell-Dependent Immune Responses in Vivo”,J. Immunol, 152:2172 (1994).
Hotamisligil and Spiegelman, Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link,Diabetes, 43:1271-1278,(1994a).
Hotamisligil et al., “Increased Adipose Tissue Expression of Tumor Necrosis Factor-α in Human Obesity and Insulin Resistance”,J. Clin. Invest, 95:2409-2415(1995).
Hotamisligil et al., “Reduced Tyrosine Chinese Activity of the Insulin Receptor in Obesity-Diabetes”,J. Clin Invest, 94:1543-1549(1994b).
Coon, Michael, et al., “Selective Pharmacologic Inhibition of Murine and Human IL-12-Dependent TH1 Differentiation and IL-12 Signaling”, J. Immuno, 163:6567-6574(1999).
“Development of TH1 CD4+T Cells Through IL-12 Produced byListeria-Induced Macrophages”, by Hsieh et al., Science, vol. 260, Apr. 23, 1993, pp. 547-549.
“Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL-2]) Induces T Helper Type 1 (Th1)- specific Immune Responses and Inhibits the Development of IL-4-producing Th Cells”, by Manetti et al., Journal of Exp. Medicine, vol. 177, Apr. 1993, pp. 1199-1204.
“Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects on Human Lymphocytes”, by Kobayashi et al., Journal of Exp. Medicine, vol. 170, Sep. 1989, pp. 827-846.
“Interleukin 12: A Key Modulator of Immune Function”, by Wolf et al., Stem Cells, vol. 12, 1994, pp. 154-168.
“Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive Immunity”, by Trinchieri, Annu. Rev. Immunol., vol. 13, 1995, pp. 251-276.
“The Role of Cytokines in Various Animal Models of Inflammation”, by Heremans et al., Lymphokine Research, vol. 8, No. 3, 1989, pp. 329-333.
“Inducible Cell Contact Signals Regulate Early Activation Gene Expression During B-T Lymphocyte Collaboration”, by Klaus et al., The Journal of Immunology, vol. 49, No. 6, Sep. 1992, pp. 1867-1875.
“Generation of Interleukin 4 (IL-4)-producing Cells In Vivo and In Vitro: IL-2 and IL-4 Required for In Vitro Generation of IL-4-producing Cells”, by Le Gros, et al., The Journal of Experimental Medicine, vol. 172, Sep. 1990, pp. 921-929.
“Inhibition of Human Interleukin-12 Production by Pentoxifylline”, by Moller et al., Immunology, vol. 91, 1997, pp. 197-203.
“The Immunology of Multiple Sclerosis and its Animal Model, Experimental Allergic Encephalomyelitis”, by Owens et al., Neurologic Clinics, vol. 13, No. 1, Feb. 1995.
“Interleukin 12”, R& D Systems Catalog, pp. 67-69, 1995.
“Long-term Treatment of Chronic Relapsing Experimental Allergic Encephalomyelitis by Transforming Growth Factor-β2”, by Racke et al., Journal of Neuroimmunology, vol. 46, 1993, pp. 175-184.
“Phosphodiesterase Inhibitor Pentoxifylline, a Selective Suppressor of T Helper Type 1—but not Type 2-associated Lymphokine Production, Prevents Induction of Experimental Autoimmune Encephalomyelitis in Lewis Rats”, by Rott et al., Eur. J. Immunol., vol. 23, 1993, pp. 1745-1751.
“The Role of IL-12 in the Induction of Organ-Specific Autoimmune Diseases”, by Trembleau et al., Immunology Today, vol. 16, No. 8, 1995, pp. 383-386.
Remington Pharmaceutical Sciences, Chapters 83-92, 1990, pp. 1519-1751.
Hesek, Dusan; Svetlik, Jan, Synth. Commun., 18(11), 1299-310 (English) 1988, abstract only.
Regnier, Gilbert L.; Guillonneau, Claude G.; Duhault, Jacques L.; Tisserand, Francoise P.; Sant-Romas, Guy; Holstorp, Sophie M., Eur. J. Med. Chem., 22(3), 243-5, 1981, abstract only.
Garmash, S.N.; Priimenko, B.A.; Skul'skaya, E.A.; Kluev, N.A., Ukr. Khim. Zh. (Russ. Ed.), 54(12), 1312-15 (Russian) 1988, abstract only.
Garmash, S.N.; Priimenko, B.A.; Skul'skaya, E.A.; Kluev, N.A., Khim. Geterotsikl. Soedin. (8) 1105-9 (Russian) 1987, abstract only.
Romanenko, N.I.; Samura, B.A.; Fedulova, I.V.; Priimenko, B.A.; Chervinskii, A. Yu.; Garmash, S.N., Khim.-Farm. Zh., 20(2), 187-90 (Russian) 1986.
Polman, C.H. et al, BMJ 2000, 321, 490-4.
Cohen, J.A. et al, J. Neuroimmun., 1999, 98 29-36.
Hallegua, D. et al, Lupus, 2000, 9, 241-251.
Khamashta, M.A. et al, Expert. Opin. Investig. Drugs, 2000, 9(7), 1581-93.
Kulmatycki, K.M. et al, Cytokine, 14(1), 2001, pp. 1-10.
Ghezzi, Pietro, Eur. Cytokine Netw., 8(3), 1997, pp. 289-290.
CAN: 110:192503a,Chemical Abstracts, vol. 110, p. 716 (1989).
CAN: 95:220048y,Chemical Abstracts, 28 Heterocycles, vol. 95, p. 513 (1981).
CAN: 94:30712s,Chemical Abstracts, vol. 94, p. 570 (1981).
CAN: 92:128861y,Chemical Abstracts, vol. 92, p. 698 (1980).
CAN: 94:47366e,Chemical Abstracts, 28 Heterocycles, vol. 94, p. 585-586 (1981).
CAN: 93:220780q,Chemical Abstracts, vol. 93, p. 536 (1980).
CAN: 94:103432n

Affiliated with

Also associated with

Rating

Uses of tricyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Uses of tricyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of tricyclic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3734439